Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

China has rapidly emerged as a global force in oncology, contributing a significant share of next-generation immunotherapies ...